Results 71 to 80 of about 1,753 (162)

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol

BMJ Open
Introduction Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin disease affecting 2%–7% of adults, with roughly 30% having moderate-to-severe disease.
Matthias Augustin, Hilde Lapeere, Anthony Bewley, Christian Vestergaard, Thomas Werfel, Eric Massana, Ismail Kasujee, Marie-Charlotte Brüggen, Marjolein S de Bruin-Weller, Khaled Ezzedine, Silvia M Ferrucci, Spyridon Gkalpakiotis, Pedro Herranz, Emma K Johansson, Tomáš Kampe, Franz J Legat, Eva Maria Rehbinder, Jacek C Szepietowski, Tiago Torres, Arnau Domenech, Volker Koscielny, Siva Narayanan, Jan Gutermuth   +22 more
doaj   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice
Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be ...
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
doaj   +1 more source

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) affects multiple areas of the body, some of which may be more refractory to treatment. We evaluated improvements in the Eczema Area and Severity Index (EASI) by body region and clinical signs for each body region in ...
Eric L. Simpson, Marjolein de Bruin-Weller, H. Chih-ho Hong, Delphine Staumont-Sallé, Andrew Blauvelt, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, Zhuqing Liu, Helena Agell, Jonathan I. Silverberg   +14 more
doaj   +1 more source

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and ...
Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong   +8 more
doaj   +1 more source

From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

Allergy, Volume 81, Issue 7, Page 2565-2567, July 2026.
Thomas Bieber, Felix Lauffer
wiley   +1 more source

Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis

BACKGROUND: Lebrikizumab, a novel monoclonal antibody targeting interleukin-13, demonstrated durable and deep response on skin and itch in patients treated for 104 weeks in recent phase 3 trials (ADvocate1, NCT04146363; ADvocate2, NCT04178967; ADjoin ...
Silverberg, Jonathan I, Casillas, Marta, Lio, Peter, Ständer, Sonja, Ding, Yuxin, Yang, Fan Emily, Wollenberg, Andreas, Del Rosso, James, Yosipovitch, Gil, Vestergaard, Christian, Agell, Helena, Gallo, Gaia, Pierce, Evangeline, Carrascosa, Jose Manuel, Stein Gold, Linda   +14 more
core   +2 more sources

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement

Dermatology Reports
Lebrikizumab, an anti-interleukin (IL)-13 monoclonal antibody, is a promising treatment for moderate-to-severe atopic dermatitis (AD). We conducted a single-center, retrospective study in 21 adults with moderate-to-severe AD who were biologic-naïve and ...
Edoardo Mortato, Claudia Paganini, Marina Talamonti, Virginia Maffei, Alfredo Belcastro, Cosimo Di Raimondo, Lorenzo Tofani, Luca Bianchi, Marco Galluzzo   +8 more
doaj   +1 more source

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient’s quality of life (QoL) and mental health.
Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres   +12 more
doaj   +1 more source

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

Frontiers in Pharmacology
BackgroundLebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.ObjectiveTo evaluate the efficacy and safety ...
Jinger Lin, Min Luo, Qianwei Zhuo, Nuo Chen, Haosong Zhang, Yue Han   +5 more
doaj   +1 more source

Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Purpose of the study Head, neck (HN), and face involvement in atopic dermatitis (AD) poses a major psychological burden and can be challenging to effectively treat.
Jenny E. Murase, Kilian Eyerich, Raj Chovatiya, H. Chih-ho Hong, Christine Bangert, Lindsay Strowd, Mette Deleuran, Amber Reck Atwater, Maria Jose Rueda, Hany Elmaraghy, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Fan Emily Yang, Jinglin Zhong, Delphine Staumont-Sallé   +14 more
doaj   +1 more source